Alpha Tau Reports 2 Complete Responses in First 3 REGAIN GBM Patients

What happened

Alpha Tau presented early data from the REGAIN study of Alpha DaRT in recurrent glioblastoma, with two of the first three patients achieving complete responses. This matches the company's guided Q2 2026 safety readout milestone, which the DeepValue report identified as a key catalyst. The data is promising but extremely early, with only three patients and the 20-F warning that interim results can change materially. The report's WAIT rating remains appropriate given the need for larger sample sizes and Japan PMS enrollment visibility. The stock may see short-term momentum, but the fundamental thesis still hinges on broader clinical and commercial execution.

Implication

The data is a step in the right direction, but investors should not overreact. The company still needs to demonstrate scalability in Japan and larger clinical datasets. The $614M market cap already embeds high expectations; additional evidence from Japan PMS and later GBM cohorts is required before upgrading.

Thesis delta

The early GBM data removes some binary risk around the Q2 readout, but does not change the fundamental thesis. The DeepValue report's base case of 50% probability and $7.75 value still stands, but the bull case probability may increase slightly if further data maintains this efficacy signal. However, with only three patients, the thesis delta is modest.